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Post-transplant diabetes mellitus: Increasing incidence in renal During the last two decades, there have been impres-
allograft recipients transplanted in recent years. sive improvements in the control of immunologic events
Background. Post-transplant diabetes mellitus (PTDM) is a that follow renal transplantation. Consequently, the num-serious complication of transplantation caused by immunosup-
ber of acute rejection episodes early post-transplant haspressive drugs. In this study, we assessed the incidence of PTDM
declined dramatically and graft survival, particularly dur-and the factors that are associated with the development of
this complication. ing the first year post-transplant, has improved substan-
Methods. The study population included 2078 non-DM renal tially [1, 2]. It is clear that in large part, these improvements
allograft recipients, transplanted since 1983 in one institution. are the consequence of the use of better immunosuppres-PTDM was diagnosed by the requirement of hypoglycemic medi-
sive protocols employing newer, more potent immuno-cations, starting more than 30 days after transplantation. Post-
suppressive drugs.transplant, all patients received cyclosporine (CsA) and predni-
sone, but none of these patients received tacrolimus. Improvements in the control of immunologic phenom-
Results. At 1, 3, 5, and 10 years after transplantation, 7, 10, ena post-transplant have been accompanied by signifi-
13, and 21% of patients developed PTDM. By multivariate cant improvements in graft survival [3]. However, highCox, the following variables correlated with a more rapid in-
patient mortality continues to be the major threat to thecrease in the number of PTDM cases: (1) older age (RR 5
success of renal transplantation [4, 5]. Because the excess2.2 comparing patients younger or older than 45 years, P ,
0.0001), (2) transplant done after 1995 (RR 5 1.7, P 5 0.003), mortality of transplant recipients is largely due to cardio-
(3) African American race (RR 5 1.6, P 5 0.003), and (4) vascular causes [6], searching for variables associated
higher body weight at transplant (RR 5 1.4, P , 0.0001). with increased cardiovascular risk and correcting thoseCompared with before 1995, since 1995, the percentage of
variables are critically important. Previous studies havepatients with PTDM has increased from 5.9 to 10.5% at one
identified several cardiovascular risk factors in patientsyear and from 8.8 to 16.9% at three years. This increase was
statistically independent from all other variables tested. How- with end-stage renal disease and in transplant patients
ever, since 1995, recipients have become significantly heavier [7, 8]. However, it has also been pointed out that the
(P , 0.0001) and older (P , 0.0001), and the average CsA cardiovascular mortality of patients with kidney diseaselevel has increased significantly (P , 0.0001). Also, since 1995,
is much higher than that of patients without kidney prob-the cumulative dose of corticosteroids has declined (P ,
lems who have a similar risk profile [9]. These results0.0001); patients received a newer, better absorbed preparation
of CsA and received mycophenolate mofetil. suggest that other cardiovascular risk factors need to be
Conclusions. The risk of PTDM increases continuously with considered in patients with kidney disease. One of those
time post-transplant. There has been an increase in the incidence factors is likely to be insulin resistance that occurs com-of PTDM in patients transplanted recently, and that increase
monly in patients receiving immunosuppressive medica-can be explained only partially by changes in the recipients’
tions and is clearly associated with increased cardiovas-characteristics. We postulate that this increase may be due to
the introduction of better absorbed CsA formulations that cular risk [10, 11].
result in higher blood levels and higher cumulative exposure The ultimate manifestation of insulin resistance in trans-
to this diabetogenic drug. plant patients is the development of post-transplant dia-
betes mellitus (PTDM). The issue of PTDM has been
recently reviewed in the literature [12]. However, impor-Key words: kidney transplantation, diabetes, cardiovascular risk, im-
munosuppression, cyclosporine A, mycophenolate mofetil. tant information is lacking about this serious complica-
tion of transplantation. In this study, we evaluated theReceived for publication May 26, 2000
development of PTDM in a large population of renaland in revised form August 2, 2000
Accepted for publication August 10, 2000 transplant recipients treated in one institution with uni-
form immunosuppressive protocols. In particular, we as-Ó 2001 by the International Society of Nephrology
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Table 1. Characteristics of the patient population
Patient characteristic Value
Age years 40.9614
Gender % males 60%
Race % African American 11%
Weight at transplant kg 74.4618
Donor type % CAD 70.7%
sessed the timing of the development of DM after trans-
plantation, the influence of different variables on that
timing, and whether the introduction of newer immuno-
suppressive medications has had effects on the overall
incidence of PTDM and its pattern of presentation. The
latter is an important consideration because in addition to
corticosteroids, newer immunosuppressive medications,
which have clearly contributed significantly to improve-
Fig. 1. Incidence of post-transplant diabetes mellitus (PTDM) with
ments in transplantation, are diabetogenic [reviewed in time post-transplant (Kaplan–Meier plots).
12]. It is our hope that a better characterization of PTDM,
first on clinical grounds, will facilitate its early detection
and treatment as well as help in the design of future trials
patients, of triple therapy with prednisone, azathioprine,to prevent the development of this devastating complica-
maintenance immunosuppression consisted and cyclo-tion of transplantation.
sporine (CsA) until the mid-1995 when azathioprine was
replaced by mycophenolate mofetil (CellCept) and Sand-
METHODS immune was substituted for Neoral. Based on these
Patient population changes in immunosuppressive protocols, patients were
divided by the date of transplantation into those trans-This study includes an analysis of 2078 patients trans-
planted prior to July 1, 1995 (N 5 1551), and thoseplanted in a single institution from August of 1982 to
transplanted after that date (N 5 527).February of 1999. This population included 606 patients
who received kidneys from living donors (LRDs) and
Analysis of the data1464 patients who received kidneys from cadaveric do-
The data are expressed as means 6 SD. Means werenors (CADs). The demographic characteristics of the
compared by Student t test or by the nonparametricpatient populations are shown in Table 1. None of these
test if the variable was not normally distributed. Thepatients had a history of DM prior to transplantation. In
incidence of PTDM over time post-transplant was ana-addition, all of the patients who required hypoglycemic
lyzed by Cox regression (univariate and multivariate)medications during the first month post-transplant were
and also by Kaplan–Meier plots after censoring patientsnot included in this cohort of patients because it was
for patient death and for graft loss.considered that these patient most likely were diabetic
prior to transplantation. No precise information about
the recipients’ family histories of DM was available; thus, RESULTS
this variable was not considered in these studies. The
Incidence of PTDMdiagnosis of PTDM was made when the patient started
Figure 1 displays the cumulative incidence of PTDMto require hypoglycemic medications, including either
with time post-transplant. During the first six-monthsoral hypoglycemic drugs and/or insulin.
post-transplant, 5.9% of patients developed this compli-All CAD kidneys were preserved by pulsatile perfu-
cation. Thereafter, the percentage of cases of PTDM in-sion. In the immediate post-transplant period, patients
creased linearly with time post-transplant. The cumula-received induction immunosuppression consisting of poly-
tive percentage of PTDM at 1, 3, 5, 10, and 15 years wasclonal (Minnesota ALG or ATG) or monoclonal anti-
7.1, 10.4, 13.2, 20.5, and 29.8%, respectively.lymphocyte antibodies (OKT3; Ortho Biotech, Raritan,
Table 2 displays the results of univariate and multivari-NJ, USA) until the serum creatinine was #2.5 mg/dL
ate Cox regression analysis and shows the variables thatwhen CsA was initiated. Since May of 1998, induction
correlate significantly with the development of PTDM.has been done with two doses of anti-interleukin-2 (IL-2)
Statistically, the strongest correlation found was betweenreceptor monoclonal antibodies (Basilxilimub, Simulect,
Novartis) instead of antilymphocyte antibodies. In most the age of the patient at the time of transplantation and
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Table 2. Variables that correlate significantly with the development
of post-transplant diabetes mellitus (PTDM) in the
study population
Univariate Multivariate
Variable analysis analysis
Ageb 2.9a 2.2,a P,0.0001
Race 1.5 1.6, P50.003
Weight at transplantationc 1.5 1.4, P,0.0001
Transplant year (,.1995) 1.9 1.7, P50.003
Gender 0.7 NS
Donor origin 1.7 NS
The data represent the results of univariate and multivariate Cox analysis.
a Values represent relative risk calculated by Cox regression
b Relative risk calculated for patients who were younger than or older than
45 years old
c Relative risk calculated for patients in the following weight groups, in kg:
,60, 60–70, 70–80, and .80
Fig. 3. Incidence of PTDM in patients classified according to their
body weight at the time of transplantation (x axis) and according to
their race: Caucasians (h) and African Americans (j).
DM after transplantation. The number of non-Caucasian,
non-African American recipients is very small in our
patient population (1.6%); thus, these patients could not
be analyzed separately. The only statistically significant
difference noted between African American and Cauca-
sian recipients was in the recipients’ weights, which were
higher in the former than in the latter group (77.5 6 20
vs. 74 6 18 kg, P 5 0.01). This difference is relevant
because the weight of the recipient at the time of trans-
plantation also correlated significantly with the develop-
Fig. 2. Incidence of PTDM with time post-transplant in recipients who ment of PTDM (Table 2). This is displayed graphically
were younger than 45 years old at transplant (heavy dashed line) or in Figure 3, where it can be observed that the risk ofolder than 45 (thin solid line; Kaplan–Meier plots).
PTDM increases significantly with increasing weight at
the time of transplantation in both Caucasians and Afri-
can Americans. However, for each weight group, the inci-
PTDM. Thus, recipients older than 45 years old were dence of PTDM was higher in African Americans than
2.9 times more likely to become diabetic post-transplant in Caucasians.
than younger recipients. Figure 2 displays Kaplan–Meier Table 2 also shows that the incidence of PTDM was
plots of the proportion of patients with PTDM in recipi- significantly higher in males than in females (15.2 vs.
ents who were younger than 45 or more than 45 years
10.4%, P 5 0.002 by chi square). However, by multivariate
old at the time of transplantation. As can be seen, the
analysis, the recipient’s gender was not an independentrisk of PTDM is significantly higher in older recipients
risk factor for diabetes. Similarly, PTDM developed moreboth during the six months post-transplant and beyond.
commonly after CAD kidney transplantation (14.5%)It should be noted in Figure 2 that the rate of increase
than in recipients of LRD (10.4%, P 5 0.01), but thein PTDM cases after the first six months is significantly
multivariate analysis indicates that the origin of the do-faster in older than in younger individuals. As demon-
nor graft is not an independent predictor of PTDM.strated in Table 2, the relationship between PTDM and
Other donor variables, including age, race, and genderthe age of the recipient is statistically independent from
did not correlate with the incidence of PTDM. Of inter-all other variables tested.
est, the incidence of PTDM did not correlate significantlyRace is also an independent predictor of PTDM (Ta-
with the amount of weight gain that the patient hadble 2). Thus, 18% of African American recipients and
12% of Caucasians (P 5 0.01 by chi square) developed during the first year post-transplant.
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Fig. 4. Incidence of PTDM in patients transplanted prior to 1995 (heavy
dashed line) or after 1995 (thin solid line; Kaplan–Meier plots).
Table 3. Comparison of the characteristics of patients transplanted
prior to or after 1995 in our institution
Patient characteristic Before 1995 After 1995 P
Demographics
Age 40614 43614 ,0.0001b
Gender % males 59% 60% NSa
Race % African American 11% 12% NSa
Weight at transplant kg 73618 78619 ,0.0001b
Donor type % cadaveric 71% 69% NSa
Immunosuppression
Prednisone mg/kg/first year 101648 91620 ,0.0001b
CsA mg/kg/first year 20576916 206661188 NSb
CsA level pg/mLd 99.8688 2426105 ,0.0001c
a Chi-square; b Student t test; c Mann-Whitney nonparametric test; d Average
level during the first year
Fig. 5. Incidence of PTDM in subgroups of patients transplanted prior
to 1995 (heavy dashed line) or after 1995 (thin solid line; Kaplan–Meier
plots). (A) Only patients .70 kg at the time of transplantation. (B)
Only recipients older than 45 years old at the time of transplant.PTDM versus transplantation year
The incidence of PTDM was 1.9 times higher in pa-
tients transplanted since 1995 compared with those trans-
planted prior to that year (Table 2). Furthermore, the July of 1995, the recipient population became signifi-
multivariate analysis shows that this correlation is statis- cantly older and heavier. However, Figure 5 re-empha-
tically independent from all other variables tested. sizes that the correlation between the date of trans-
Kaplan–Meier curves of PTDM in recipients trans- plantation and PTDM is statistically independent from
planted prior to and after 1995 are displayed in Figure the age and/or weight of the recipient. Thus, it can be
4. As can be seen, since July of 1995, the risk of PTDM seen that the incidence of PTDM is significantly higher
has increased both during the first six-months post-trans- in obese recipients (Fig. 5, top) and in recipients older
plant and beyond, with a significantly faster rate of in- than 45 years old (Fig. 5, bottom) transplanted after 1995
crease in the number of PTDM cases. Thus, at one and than before that year. It should also be noted in Table
three years, the incidences of PTDM were 6 and 8.7% 3 that significant changes in immunosuppression have
in patients transplanted before 1995 and 10.6 and 17.1% also occurred since 1995. Thus, the cumulative dose of
corticosteroid received by patients transplanted afterin those transplanted since 1995.
It is likely that several factors contributed to the in- July of 1995 was significantly lower than prior to that
date. This reduction is not the result of a protocol changecreased occurrence of PTDM since 1995. For example,
Table 3 displays a comparison between the patient char- but the result of the significant decrease in the number
of acute rejection episodes during the first year post-acteristics prior to and after 1995. As can be seen, after
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transplant (before 1995, 1 6 1.4 episodes per patient vs. studies showed that abnormalities in insulin/glucose me-
tabolism are racially diverse [16]. Thus, it is likely thatafter 1995, 0.5 6 0.5, P , 0.0001 by Wilcoxon). The
cumulative dose of CsA has not changed significantly the mechanisms of PTDM in individuals of different
racial groups may also be different.since 1995 (Table 3). However, the average CsA level
during the first year post-transplant was significantly We showed here that weight is a risk factor for PTDM
and that African American recipients are significantlyhigher in patients transplanted after 1995 than in those
transplanted before that date, most likely reflecting the heavier than Caucasians. However, we showed that for
patients with similar body weights, the risk of PTDM isuse of better absorbed formulations of CsA.
still higher in African Americans. It should be empha-
sized that in renal transplant recipients, the risk of PTDM
DISCUSSION
increases continuously for every increment of body
In the present study, we evaluated the incidence of weights above 60 kg, clearly below what may be consid-
PTDM in a large group of renal allograft recipients, ered to be an overweight range for most patients. Weight
transplanted in a single institution, and treated with uni- gain is a very common problem post-transplantation.
form CsA-based immunosuppressive protocols. The inci- However, in this study, we did not find a significant
dence of PTDM reported here is similar to that noted correlation between weight gain during the first year
in other studies. However, there is a significant variability post-transplant and PTDM but rather between pretrans-
in the reported incidence of PTDM, most likely because plant weight and PTDM.
of at least three reasons. First, the criteria used to diag- For all racial and weight groups and for both patients
nose PTDM are quite variable among studies [12]. Sec- transplanted in the remote past or more recently, the age
ond, variability in the immunosuppressive protocols used of the recipient at the time of transplantation is statisti-
in different transplant centers will have an impact in cally the strongest predictor of the risk for PTDM. The
the incidence of PTDM. For example, the incidence of increased risk of PTDM in older recipients has two dis-
PTDM is significantly higher in transplant recipients tinct components. First, compared with younger recipi-
treated with tacrolimus than in those treated with CsA ents, patients older than 45 years have a marked increase
[13]. Finally, the reported incidence of PTDM will vary in the incidence of PTDM during the first six months
according to the length of patient follow-up because, post-transplant when the patient is receiving the highest
as shown here, the percentage of patients who develop doses of corticosteroids. Second, beyond six months
PTDM increases continuously post-transplant. Regard- post-transplant, the rate of increase in the number of
ing this latter point, these results showed that there are cases of PTDM is faster in older than in younger individ-
two distinct periods of PTDM development. The first, a uals. It seems reasonable to postulate that PTDM may
period of high risk, comprises the first six-months post- comprise at least two subpopulations of individuals. The
transplant. The second comprises the rest of the post- first, including patients who develop diabetes early post-
transplant time when there is a continuous increase in transplant, most likely represents patients who had insu-
the number of patients with PTDM. In this study, we lin resistance prior to the transplant that was made worse
diagnosed PTDM as the need for hypoglycemic medica- by high doses of steroids, requiring the initiation of hypo-
tions. Thus, the incidence of PTDM reported here, al- glycemic therapy. The second group of patients who
though high, is likely to be an underestimate of the true develop PTDM beyond six months post-transplant and
magnitude of the problem. This is particularly relevant may represent newly acquired diabetic individuals, either
when we consider that the incidence of PTDM has in- with hyperinsulinemia and insulin resistance or with hy-
creased rather sharply since 1995. poinsulinemia [12].
The results of this analysis showed that the risk of For the first time, we showed here that the incidence
PTDM is higher in African American recipients than of PTDM has increased rather sharply since 1995 to the
in Caucasian recipients. This finding is consistent with present time. In fact, the number of PTDM cases has
previous observations in transplant recipients [12] and nearly doubled since 1995, and the linear shape of the
also with the observation that, in the general population, Kaplan–Meier plots suggests that more than 40% of re-
the incidence of type II DM is significantly higher in cipients transplanted since 1995 may acquire DM within
African Americans than in Caucasians [14, 15]. Further- five-years post-transplant. These results suggest that
more, among nondiabetic subjects, the incidence of hy- the increase in PTDM is multifactorial, including both
perinsulinemia and insulin resistance is also higher in changes in patients’ risk profiles and changes in immuno-
African Americans than in Caucasians [15]. Thus, it is suppressive medications. Thus, since 1995, renal trans-
likely that more African Americans than Caucasians plant recipients in our institution have become signifi-
have insulin resistance prior to transplantation, and in cantly heavier and significantly older. However, the
these patients, treatment with immunosuppressive drugs increased incidence of PTDM since 1995 is statistically
independent from these two factors. We postulate thatthat are diabetogenic would result in PTDM. Previous
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